van Eeghen Elmer E, Bakker Sandra D, Fransen Gerwin, Flens Marcel J, Loffeld Ruud J L F
Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands.
Department of Radiology, Zaans Medisch Centrum, Zaandam, The Netherlands.
J Gastrointest Oncol. 2017 Aug;8(4):625-628. doi: 10.21037/jgo.2017.04.05.
Evaluate the preoperative TN stage with MR and the postoperative stage with histology.
Patients diagnosed with rectal cancer (2002-2015) and a pre-operative MR were included. A chart review was done. Pathology reports were evaluated for the post-operative tumor stage. Down staging was defined as a lower disease stage in the resection specimen compared with the pre-operative MR. Upgrading ("progression") was defined as a higher disease stage in the resection specimen. The study was approved by ethical committee of the Zaans Medisch Centrum.
From 176 out of 231 operated patients a pre-operative MR was available for evaluation. 142 patients (80.7%) underwent neo-adjuvant treatment; the remainder 19.3% underwent immediate surgery. Neo-adjuvant therapy resulted in significant down staging. However, almost 14% of patients had a higher TN stage as determined by the pre-operative MR. In patients who underwent immediate surgery the percentage with "progression" was 30%. The number of patients with stage 1 and 2 were higher in the group not treated with neo-adjuvant therapy. There was no significant difference in tumor stage as determined by histological examination of the resection specimen.
The diagnostic accuracy of the MR is not perfect. Underestimation as well as overestimation of the tumor occurred both in the patients treated with radiotherapy as well as those who underwent immediate operation. As such, MR results should be interpreted with caution when devising a treatment strategy.
通过磁共振成像(MR)评估术前TN分期,并通过组织学评估术后分期。
纳入2002年至2015年期间诊断为直肠癌且术前行MR检查的患者。进行病历回顾。评估病理报告以确定术后肿瘤分期。降期定义为切除标本中的疾病分期低于术前MR检查结果。升期(“进展”)定义为切除标本中的疾病分期高于术前。本研究获得赞斯医学中心伦理委员会批准。
231例接受手术的患者中,有176例术前行MR检查可供评估。142例患者(80.7%)接受了新辅助治疗;其余19.3%的患者接受了直接手术。新辅助治疗导致显著降期。然而,近14%的患者术前MR检查确定的TN分期更高。接受直接手术的患者中“进展”的比例为30%。未接受新辅助治疗的组中1期和2期患者数量更多。切除标本组织学检查确定的肿瘤分期无显著差异。
MR的诊断准确性并不完美。接受放疗的患者以及接受直接手术的患者均出现肿瘤低估和高估的情况。因此,在制定治疗策略时,应谨慎解读MR结果。